PCK1 and myeloid sarcoma: In a secondary analysis, we investigated whether a surrogate marker for HLA B*4402 modifies the effects of the PCK1 variant (rs8192708) on baseline brain volume given that we have previously reported an association between HLA B*4402 and higher BPF in MS subjects [7].